It can be a shock to learn that you have a serious medical problem like wet age-related macular degeneration. Realistically, the condition is likely to disrupt your everyday life, at least for a while ...

Macular degeneration is a leading cause of vision loss, especially in people over the age of 50. It affects the macula, a ...

New treatments for macular degeneration may help preserve your eyesight for longer, without the need for frequent injections. Some of these treatments include retinal gene therapy and the "port" ...

For every 10 people who have macular degeneration, one or two will get wet AMD. But spotting the wet AMD symptoms early will help you get treatment and prevent vision loss. Blurry vision or other ...

Wet macular degeneration is a specific subtype of age ... These tests may also be used to assess your response to treatment. Fluorescein angiogram: A fluorescent dye is injected into your arm ...

This article discusses some of the new treatments that are emerging to treat both wet and dry age-related macular degeneration (AMD). Related: Wet vs. Dry Age-Related Macular Degeneration New ...

Since July 2024, faricimab has also been approved in Europe for the treatment of visual impairment due to macular edema ...

The FDA has approved a first-of-its-kind treatment for dry age-related macular degeneration (AMD), a leading cause of blindness in adults over 55.

A new eye drop therapy offers a non-invasive alternative for treating dry age-related macular degeneration. Massively ...

Shares of Outlook Therapeutics jumped after the company said it continues to progress the development of its treatment for wet age-related macular degeneration, which causes blurred or reduced central ...

Jedd Comiskey, Senior Vice President, Head of Europe, highlights the recent NICE recommendation of LYTENAVA™ (bevacizumab gamma) for the treatment of wet AMD Access the segment here ISELIN, N.J., Jan.

AVMX-110 is under development for the treatment of wet age-related macular degeneration (wAMD) and polypoidal choroidal vasculopathy (PCV). The drug candidate comprises a recombinant adeno-associated ...